The Life Sciences Report
Other Streetwise Reports
The Gold Report The Energy Report The Life Sciences Report The Metals ReportMore Experts
"NEO is a small but focused diagnostic company with numerous competitive advantages." (4/4/13) NeoGenomics Laboratories - The Life Sciences Report Interview with Grant Zeng More >
"The Abstral acquisition has transformed GALE from a development biotech company into a commercial organization." (4/4/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Grant Zeng More >
"I believe the monoclonal antibody technology that SYN is working on for pertussis is especially interesting." (3/28/13) Synthetic Biologics Inc. - The Life Sciences Report Interview with Keith Markey More >
"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"If phase 2b ASSURE trial results show a significant decrease in atherosclerotic plaque volume, it will be a huge win for RVX." (3/7/13) Resverlogix Corp. - The Life Sciences Report Interview with George Zavoico More >
Sector Experts
Subscribe to
Streetwise Reports
Companies Commented On
- Amylin Pharmaceuticals Inc.
- Anika Therapeutics, Inc.
- Ariad Pharmaceuticals Inc.
- Avanir Pharmaceuticals Inc.
- Biogen Idec Inc.
- BioMarin Pharmaceuticals
- Bristol-Myers Squibb Co.
- Celgene Corp.
- Gilead Sciences Inc.
- Human Genome Sciences Inc.
- ImmunoCellular Therapeutics Ltd.
- Immunomedics, Inc.
- Ligand Pharmaceuticals Inc.
- Lpath Inc.
- United Therapeutics
- Vertex Pharmaceuticals Inc.
Carol Werther
Summer Street Research Partners
Prior to joining Summer Street Research Partners, Carol Werther worked as a biotechnology consultant for several firms, including Winslow Management and Rx Capital. She has also held senior biotechnology analyst positions at Think Equity and Adams Harkness & Hill. Ms. Werther was recognized by The Wall Street Journal's "Best on the Street Survey" in 2000 and 2001. She received an MBA from New York University, Stern School of Business, and holds an MS and BS in nutrition sciences from the University of Alabama in Birmingham and Cornell University, respectively.
Recent Interviews
Being Selective in Biotech: Carol Werther (3/1/12) In an industry steeped in complex research and speculative drug development, successful biotech investing requires real sophistication. Senior Biotechnology Analyst Carol Werther of Boston-based Summer Street Research Partners brings her experience to bear on the trinity of unmet needs, reimbursement and what physicians are willing to support with their prescription pads. In this exclusive interview with The Life Sciences Report, Werther shares her high-percentage picks that present opportunities for significant returns.
Recent Quotes
"We are reiterating our Buy rating on LPTN." (1/4/13) Lpath Inc. - Carol Werther, Summer Street Research Partners More >
"IMUC is significantly undervalued." (7/28/11) ImmunoCellular Therapeutics Ltd. - Carol Werther, Summer Street Research Partners More >
Notable Quotes
"I think GALE has a good shot on its phase 3 NeuVax trial." (5/23/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Echo He More >
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >